Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01097343 · ClinicalTrials.gov registry record · Phase 2
Clopidogrel Pharmacogenomics Project
A Phase 2 study of Disease Susceptibility, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT01097343 is a Phase 2 study of Disease Susceptibility that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01097343, a Phase 2 study of Disease Susceptibility, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Loss-of-function mutation of the gene encoding the CYP450 2C19 enzyme has emerged as a likely determinant of resistance to clopidogrel therapy. The primary hypothesis of the proposed research is that among patients with confirmed loss-of-function alleles of the CYP2C19 gene, increasing the maintenance clopidogrel dose from 75 to 150 mg will result in significant reduction in the rate of measured clopidogrel resistance defined by multiple measures of platelet function
Conditions Studied
Interventions
- DRUG clopidogrel 75 mg
- DRUG Clopidogrel 150 mg
Study Locations (1)
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01097343
The ClinicalTrials.gov registry entry for NCT01097343 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Disease Susceptibility appearing as the primary indexed condition, and to 2 interventions - of which clopidogrel 75 mg is the first listed.
NCT01097343 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01097343 about?
NCT01097343 is a clinical study titled "Clopidogrel Pharmacogenomics Project". Loss-of-function mutation of the gene encoding the CYP450 2C19 enzyme has emerged as a likely determinant of resistance to clopidogrel therapy. The primary hypothesis of the proposed research is that among patients with confirmed loss-of-function alleles of the CYP2C19 gene, increasing the maintenan...
What is the current status of trial NCT01097343?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2010-03. Estimated completion is 2011-05.
What conditions does trial NCT01097343 study?
This clinical trial studies the following conditions: Disease Susceptibility.
What interventions are being tested in trial NCT01097343?
The interventions under investigation include: clopidogrel 75 mg (DRUG), Clopidogrel 150 mg (DRUG).
Who is sponsoring clinical trial NCT01097343?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01097343 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.